Prostate cancer trials recruiting in Connecticut

All Prostate cancer trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
  NCT06925737 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven, West Haven
• A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
  NCT07258407 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth
  NCT07454603 · Phase: Not specified · Ages: 45 Years to 80 Years · Sex: Male · Connecticut: Branford
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
  NCT05800665 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  NCT06842498 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
  NCT06990880 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
  NCT03460977 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Norwalk
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
  NCT06136650 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Connecticut: Hartford
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
  NCT05652686 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
  NCT06457919 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Connecticut: Hartford
• A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
  NCT05751434 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: Hartford
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
  NCT03972657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
  NCT05806515 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: Derby, Fairfield, Glastonbury, Greenwich
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Connecticut: West Haven
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
  NCT06592924 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Connecticut: West Haven
• Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
  NCT04373564 · Phase: Phase 4 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Connecticut: New Haven
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
  NCT07080242 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
  NCT05011383 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: West Haven
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · Connecticut: Manchester
• International Registry for Men With Advanced Prostate Cancer (IRONMAN)
  NCT03151629 · Phase: Not specified · Ages: 21 Years and older · Sex: Male · Connecticut: New Haven
• Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
  NCT05803941 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: Male · Connecticut: Hartford
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Connecticut: Hartford
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Connecticut: Hartford, Norwalk
• Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
  NCT06100705 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Connecticut: Guilford, New Haven, Stamford, Trumbull
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
  NCT06800313 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
  NCT05519449 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · Connecticut: New Haven
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
  NCT06136624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Study of PF-07248144 in Advanced or Metastatic Solid Tumors
  NCT04606446 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
  NCT05176483 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
  NCT06458712 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Stamford
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Connecticut: New Haven
• The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
  NCT06111781 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Connecticut: New Haven